Press Releases

2011 achievements and 2012 prospects

BioAlliance Pharma confirms the dynamics of its core business BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces its 2011 achievements and 2012 prospects. The year 2011 was marked by major achievements of its key assets and by determining strategic orientations that enable BioAlliance Pharma to enter 2012 with strong growth…read more →

BioAlliance Pharma announces two key steps with its AMEP™ biotherapy for metastatic melanoma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces two key steps in the development of its AMEP™ biotherapy with the submission to the French drug agency (Afssaps) of a phase I/II clinical trial in the metastatic melanoma and the grant of a European patent covering the product until 2022. AMEP™…read more →

BioAlliance Pharma: New achievements in the collaboration With its strategic European partner, Therabel

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces the achievement of the reserved capital increase and the payment of the €1 million milestone, as provided in the commercialization agreement signed with the Therabel Group for Loramyc® in Europe. Therabel has actually subscribed for the maximum amount authorized by the General…read more →

BioAlliance Pharma ranked as France’s fastest growing company in the 2011 « Deloitte Technology Fast 50 »

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announced that it has won first prize in “Deloitte’s Technology Fast 50” 2011 ranking of fastest-growth technologies companies, as well first prices “Biotech and Health sector” and “Nyse Euronext” in national Fast 50 ranking. BioAlliance Pharma also received first prize in regional “Ile-de-…read more →

BioAlliance Pharma reports its consolidated turnover for Q3 And announces progress for Loramyc® commercialization in Italy

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €332,000 for the quarter of 2011 and announced progress for Loramyc® commercialization in Italy. This turnover is nearly equally made of our partners’ international activities on Loramyc®/Oravig® (royalties and sales) and to the staggered upfront payments received from…read more →

BioAlliance Pharma announces: Grant of « orphan designation » for clonidine Lauriad™ in Europe

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announced that clonidine Lauriad™ has been granted orphan designation by the European Commission in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer. Oral mucositis is a very frequent inflammation of the oral mucosa in head and neck cancer…read more →

A major step forward in the development of Sitavir®: European registration file submission for the treatment of recurrent orofacial herpes

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announced submission of its Sitavir® (acyclovir Lauriad™) European registration dossier through a European decentralized procedure*. BioAlliance Pharma has conceived and developed Sitavir® for the treatment of recurrent orofacial herpes in immunocompetent patients presenting more than 4 episodes a year. Sitavir® is an innovative…read more →

Consolidated accounts for the first semester of 2011 And recent significant key events

• Key achievements in the clinical development of orphan oncology products • Strongly reinforced cash position after successful capital increase in August, aiming to finance R&D programs • Optimization of international commercial partnerships with Loramyc® in the development of the leader orphan oncology product Livatag®: The presentation of positive phase II results showing a doubled median survival when compared with…read more →

BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP® biotherapy for metastatic melanoma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis. The objectives of this first phase I trial were to evaluate the safety of intratumoral electrotransfer of AMEP® biotherapy and…read more →

BioAlliance Pharma announces 2 key decisions green light granted from french agency for Livatag® phase |||

Full us rights regained for oravig® BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces: • Following PAR Strativa restructuring and change of strategy including recent acquisition of generic portfolio, BioAlliance Pharma has decided to regain full US commercialization rights for Oravig®. The transfer, with no significant impact on BioAlliance Pharma…read more →

Presentation of Livatag® survival results at the international liver cancer congress in Hong Kong

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag® at the annual congress of ILCA (International Liver Cancer Association), the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists. Pr. Philippe…read more →

BioAlliance Pharma initiates the clinical batches production of Livatag® (doxorubicin Transdrug™) for its phase III clinical trial

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces the initiation of the clinical batches production of Livatag® (doxorubicin Transdrug™) for its phase III clinical trial in primary liver cancer. This production will be performed by qualified companies for injectable cytotoxic products in nanoparticle form. The BioAlliance Pharma’s team specialized in…read more →

Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products”

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €576,000 for the second quarter of 2011. This turnover is mainly made of recurring revenues from Loramyc®/Oravig®. It also comprises an amount of €113,000 corresponding to the staggering of the upfront payment received from BioAlliance new partner Sosei,…read more →

Successful capital increase for BioAlliance Pharma

Over-subscribed transaction €16.64 million raised (Offering notice number 11-280 dated 30th June 2011 approved by the French financial market regulator AMF) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces its successful capital increase, with maintenance of preferential subscription rights launched on July 1st, 2011, for a total of €16,64 million…read more →